EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

Romain Donne iD, Amaia Lujambio iD

Hepatology · 2023-05 · 77 (5) · 1773-1796

DOI: 10.1002/hep.32740 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hepatology, online erschienen am 17.04.2023. Verfasst von Romain Donne und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Sciences , Icahn School of Medicine at Mount Sinai , New York , New York , USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 635-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy. In the last few years, immune‐checkpoint inhibitors (ICIs) have revolutionized cancer therapy and have gained an increased interest in the treatment of HCC. In 2020, the combination of atezolizumab (anti‐programmed death‐ligand 1) and bevacizumab (anti–vascular endothelial growth factor) improved overall survival over sorafenib, resulting in Food and Drug Administration (FDA) approval as a first‐line treatment for patients with advanced HCC. Despite these major advances, a better molecular and cellular characterization of the tumor microenvironment is still needed because it has a crucial role in the development and progression of HCC. Inflamed (hot) and noninflamed (cold) HCC tumors and genomic signatures have been associated with response to ICIs. However, there are no additional biomarkers to guide clinical decision‐making. Other immune‐targeting strategies, such as adoptive T‐cell transfer, vaccination, and virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, different cellular players, current available immunotherapies, and potential immunotherapy modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansSorafenibImmunotherapyTumor Microenvironment

Substanzen

Sorafenib

Autor:innen und Institutionen

  • Department of Oncological Sciences , Icahn School of Medicine at Mount Sinai , New York , New York , USA.
  • Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , New York , USA.
  • Icahn School of Medicine at Mount Sinai , The Precision Immunology Institute , New York , New York , USA.
  • Graduate School of Biomedical Sciences , Icahn School of Medicine at Mount Sinai , New York , New York , USA.

ORCID-Profile: Romain Donne, Amaia Lujambio

Förderung

  • NCI NIH HHS

Zitieren

APA

Donne, R., & Lujambio, A. (2023). The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 77(5), 1773-1796. https://doi.org/10.1002/hep.32740

Vancouver

Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773-1796. doi:10.1002/hep.32740

BibTeX
@article{Donne2023,
  author = {Donne, Romain and Lujambio, Amaia},
  title = {The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma},
  journal = {Hepatology},
  year = {2023},
  volume = {77},
  number = {5},
  pages = {1773--1796},
  doi = {10.1002/hep.32740}
}
Kostenlos starten →